ACM
SPRY icon

Aster Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Aster Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-349
Closed -$4.39K – 1237
2026
Q1 		$4.39K Buy
349
+196
+128% +$1.88K ﹤0.01% 691
2025
Q4 		$1.78K Buy
+153
New +$1.49K ﹤0.01% 963
2025
Q3 		– Sell
-268
Closed -$4.68K – 1337
2025
Q2 		$4.68K Sell
268
-2,823
-91% -$40.7K ﹤0.01% 873
2025
Q1 		$32.4K Buy
3,091
+2,483
+408% +$29.9K 0.01% 909
2024
Q4 		$6.41K Buy
+608
New +$8.52K ﹤0.01% 829

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Aster Capital Management's SPRY Position: Q2 2026 in Review

Aster Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 349 shares — an estimated $4.39K sold.

Aster Capital Management first reported a position in SPRY in Q4 2024 and held it in 5 quarters. The position peaked at $32.4K in Q1 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Aster Capital Management reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 349 ARS Pharmaceuticals shares in Q2 2026, an estimated $4.39K.
  • Aster Capital Management first reported a position in ARS Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • Aster Capital Management's ARS Pharmaceuticals position peaked at $32.4K in Q1 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.